Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'- tetrahydrofuryl)-5-fluorouracil

Clinical Cancer Research

Volumn 4, Issue 9, 1998, Pages 2085-2088

  Ho, D H ^a   Pazdur, Richard ^a   Covington, Wendy ^a   Brown, Nita ^a   Huo, Yuang Yi ^a   Lassere, Yvonne ^a   Kuritani, Jun ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; TEGAFUR; URACIL;

ADENOCARCINOMA; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CATHETER INFECTION; CLINICAL ARTICLE; DIARRHEA; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RECTUM CARCINOMA; VEIN THROMBOSIS;

ADENOCARCINOMA; ADMINISTRATION, ORAL; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASMS; PRODRUGS; TEGAFUR; URACIL;

EID: 0031691506     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Lokich, J., Bothe, A., Fine, N., and Perri, J. Phase I study of protracted venous infusion of 5-fluorouracil. Cancer (Phila.), 48: 2565-2568, 1981.
2. Lokich, J., Ahlgren, J. D., Gullo, J. J., Philips, J. A., and Fryer, J. G. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program Study. J. Clin. Oncol., 7: 425-432, 1989.
3. Hansen, R. M., Quebbeman, E., and Anderson, T. 5-Fluorouracil by protracted venous infusion. A review of current progress. Oncology, 46: 245-250, 1989.
4. Vogelzang, N. Continuous infusion chemotherapy: a critical review. J. Clin. Oncol., 2: 1289-1304, 1984.
5. Meta-Analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J. Clin. Oncol., 16: 301-398, 1998.
6. 1-(2′-tetrahydrofuryl)-5-fluorouracil (FT-207). Gan No Rinsho, 17: 731-742, 1971.
7. Smolyanskaya, A. Z., and Tugarinov, O. A. The biological activity of antitumor antimetabolite "ftorafur." Neoplasm, 19: 341-345, 1972.
8. Ikenaka, T., Shiraska, T., Kitano, S., and Fujii, S. Effect of uracil on metabolism of 5-fluorouracil in vitro. Gann, 70: 353-359, 1979.
9. Fujii, S., Ikenaka, T., Fukushima, M., and Shirasaki, T. Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil and 1-(2-tetrahydrofuryl)-5-fluorouracil. Gann, 69: 763-772, 1978.
10. Majima, H. Phase I and Phase II study of coadministration of uracil and FT-207 (UFT therapy). Gan To Kagaku Ryoho, 7: 1383-1387, 1980.
11. Tamura, Y., Okina, M., Hongo, H., Nakayasu, F., Tokunaga, M., Hosoba, S., Itoh, T., Nimoto, M., and Hattori, T. Phase II study of UFT by collaborative study. Gan To Kagaku Ryoho, 8: 302-307, 1981.
12. Watanabe, H., Yamamoto, S., and Naito, T. Clinical results of oral UFT therapy under cooperative study. Gan To Kagaku Ryoho, 7: 1588-1596, 1980.
13. Ota, H., Taguchi, T., and Kimura, M. Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer Chemother. Pharmacol., 22: 333-338, 1988.
14. Pazdur, R., Lassere, Y., Rhodes, V., Ajani, J. A., Sugarman, S. M., Patt, Y. Z., Jones, D. V., Markowitz, A. B., Abbruzzesse, J. L., Bready, B., and Levin, B. Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. J. Clin. Oncol., 12: 2296-2300, 1994.
15. Muggia, F. M., Wu, X., Spicer, D., Groshen, S., Jeffers, S., Leichman, G., Leichman, L., and Chan, K. K. Phase I and pharmacokinetic study of oral UFT, a combination of the 5-fluorouracil prodrug tegafur and uracil. Clin. Cancer Res., 2: 1461-1467, 1996.
16. Meropol, N. J., Rustum, Y. M., Petrelli, N. J., Rodriquez-Bigas, M., Frank, C., Ho, D. H., Kurowski, M., and Creaven, P. J. A phase I and pharmacokinetic study of oral uracil, ftorafur and leucovorin in patients with advanced cancer. Cancer Chemother. Pharmacol., 37: 581-586, 1996.
17. Marunaka, T., Umeno, Y., Yoshida, K., Minami, Y., and Fujii, S. High pressure liquid chomatographic determination of ftorafur [1-tetrahydro-2-5-furanyl)-5-fluorouracil] and uracil in biological materials after oral administration of uracil plus ftorafur. J. Pharm. Sci., 69: 1296-1300, 1980.
18. Rowland, M., and Tozer, T. N. Clinical Pharmacokinetics: Concepts and Applications, Ed. 2, pp. 25, 415-416. Philadelphia: Lea & Febiger, 1989.
19. Ritschel, W. A. Handbook of Basic Pharmacokinetics, pp. 235-240. Hamilton, IL: Drug Intelligence Publications, 1976.
20. Sokal, R. R., and Rohlf, F. J. Biometry, Ed. 2. New York: W. H. Freeman & Co., 1981.
21. Collins, J. M., Dedrick, R. L., King, F. G., Apeyer, J. L., and Myers, C. E. Nonlinear pharmacokinetic models for 5-fluorouracil in man: intravenous and intraperitoneal routes. Clin. Pharmacol. Ther., 28: 235-246, 1980.
22. Ho, D. H. W., Townsend, L., Luna, M. A., and Bodey, G. P. Distribution and inhibition of dihydrouracil dehydrogenase activities in human activities in human tissues using 5-fluorouracil as a substrate. Anticancer Res., 6: 781-784, 1986.
23. Harris, B. E., Song, R., Soong, S. J., and Diasio, R. B. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res., 50: 197-201, 1990.
24. Remeck, S. C., Grem, J. L., Fischer, P. H., Tutsh, K. D., Alberti, D. B., Nieting, L. M., Tombes, M. B., Bruggink, J., Wilson, J. K. V., and Trump, D. L. Phase I trial of 5-FU and dipyridamole administered by seventy-two hour concurrent continuous infusion. Cancer Res., 50: 2667-2672, 1990.
25. Pazdur, R., Lassere, Y., Diaz-Canton, E., Bready, B., and Ho, D. H. Phase I trial of uracil-tegafur (UFT) plus oral leucovorin: 14-day schedule. Invest. New Drugs, 15: 123-128, 1997.
26. Dorr, R. T., and Von Hoff, D. D. 5-Fluorouracil. In: R. T. Dorr and D. D. Von Hoff (eds.), Cancer Chemotherapy Handbook, pp. 500-515. Norwalk, CT: Appleton & Lange, 1994.